ArticleInfluenza and other respiratory viruses2025
COVID-19 Hospitalizations, Vaccine Uptake, Vaccination Guidelines, and Vaccine Availability in Six Middle-Income Countries and Areas in Europe, May 2022-April 2024.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundUpdated regional data on COVID-19 epidemiology and vaccination can inform vaccine policies and implementation strategies.
methodsWe used surveillance data on patients hospitalized from the European SARI Vaccine Effectiveness (EuroSAVE) network to describe COVID-19 epidemiology and COVID-19 vaccine uptake among adults hospitalized with severe acute respiratory infection (SARI) in six middle-income countries and areas (CAs) in the WHO European region during 2022-2024. For SARI patients, we collected data on demographics, comorbidities, vaccination status, and hospital course, and a respiratory specimen, which was tested for SARS-CoV-2 by RT-PCR. In October 2024, we surveyed national public health institute staff on national COVID-19 vaccine guidelines and availability.
resultsOf SARI patients, 833/3982 (20.9%) and 367/3752 (9.8%) tested positive for SARS-CoV-2 during May 2022-April 2023 and May 2023-April 2024, respectively. Of COVID-19 patients, 857 (71.4%) were ≥60 years old and 713 (59.4%) had ≥1 comorbidity. A higher proportion of COVID-19 patients required mechanical ventilation (30 [8.2%] vs. 23 [2.8%], p <0.001) and intensive care (70 [8.4%] vs. 48 [13.1%], p =0.016) during May 2023-April 2024 compared to May 2022-April 2023. COVID-19 vaccination in the last 12 months decreased from 25% in 2022-2023 to 3% in 2023-2024. Most CAs had not updated their COVID-19 vaccination guidelines to recommend annual vaccination, and only two had vaccines available.
conclusionsAlthough COVID-19 was associated with severe disease among SARI patients, COVID-19 vaccination uptake was low among priority populations recommended for vaccination by WHO guidance. Continued efforts to understand reasons for low vaccine uptake and improve vaccine access will help protect those at greatest risk for COVID-19-associated morbidity and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.